Form 4 Filing for Acrivon Therapeutics, Inc. - Officer Stock Acquisition

This filing details a Form 4 submission by Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV). On May 18, 2026, Devroe acquired 72,981 shares of Common Stock through the vesting of restricted stock units (RSUs). The acquisition was made at a price of $0.0 per share, indicating a non-purchase transaction, likely related to equity compensation. Following this transaction, Devroe now owns 146,953 shares of Acrivon Therapeutics, Inc. common stock. The RSUs are subject to vesting schedules, with a portion vesting on November 18, 2026, and the remainder vesting in subsequent quarterly installments, contingent upon Devroe's continued employment with the company.